Blood · 2011 · 69 citations · 47 references
MedicineHematologyOncologyCell TherapyStem Cell TransplantationTransplant ImmunologyAutologous Stem Cell TransplantationCancer Stem CellsEngraftment MonitoringHematopoietic Stem Cell TransplantationAutologous Stem Cell InfusionAutologous Stem Cell TherapyChronic Lymphocytic Leukemia TherapyRefractory Chronic Lymphocytic LeukemiaSurvival After Autologous TransplantationTransplantation For Hematologic Malignancies
Long-term responses have been reported after autologous stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL). We conducted a prospective, randomized trial of ASCT in previously untreated CLL patients. We enrolled 241 patients < 66 years of age with Binet stage B or C CLL. They received 3 courses of mini-CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone/prednisolone) and then 3 courses of fludarabine. Patients in complete response (CR) were then randomized to ASCT or observation, whereas the other patients were randomized to dexamethasone, high-dose aracytin, cisplatin (DHAP) salvage followed by either ASCT or 3 courses of fludarabine plus cyclophosphamide (FC). The primary end point was event-free survival (EFS). After up-front treatment, 105 patients entered CR and were randomized between ASCT (n = 52) and observation (n = 53); their respective 3-year EFS rates were 79.8% and 35.5%; the adjusted hazard ratio was 0.3 (95% CI: 0.1-0.7; P = .003). Ninety-four patients who did not enter CR were randomized between ASCT (n = 46) and FC (n = 48); their respective 3-year EFS rates were 48.9% and 44.4%, respectively; the adjusted hazard ratio was 1.7 (95% CI: 0.9-3.2; P = .13). No difference in overall survival was found between the 2 response subgroups. In young CLL patients in CR, ASCT consolidation markedly delayed disease progression. No difference was observed between ASCT and FC in patients requiring DHAP salvage.
47
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner, Stephan Stilgenbauer, Axel Benner et al. · New England Journal of Medicine · 2000 · 3.3K citations
Life Sciences, Genetics, Oncology +17
Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text
Medicine, Hematology, Oncology +14
Rajendra N. Damle, Tarun Wasil, Franco Fais et al. · Blood · 1999 · 2.6K citations
Medicine, Hematology, Oncology +12